While hormonal therapy has been the usual and appropriate treatment of advanced or
metastatic prostatic cancer for the past 50 years, the recent development of new therapeutic …

PURPOSE: High grade prostatic intraepithelial neoplasia is likely a premalignant lesion of
the prostate. Decreasing the frequency of high grade PIN may decrease the risk of prostate …

BACKGROUND Combined androgen blockade (CAB)(medical or surgical castration plus
antiandrogen therapy) is considered by many to be the optimal endocrine maneuver for …

Background The nonsteroidal androgen-receptor antagonist flutamide is given at high dose
(> 750 mg/day) to men with prostate cancer but can cause hepatotoxicity within 3 months; …

OBJECTIVE: Because of its long latency, slow growing nature, and high prevalence,
prostate cancer is the best model for chemoprevention. High-grade prostate intraepithelial …

Background. A prospective randomized study was designed to determine whether flutamide
(FLU) administered before treatment with a luteinizing hormone-releasing hormone agonist …

OBJECTIVE To present the long‐term outcome of patients with locally advanced or
metastatic prostate carcinoma treated by first‐line antiandrogen monotherapy. PATIENTS …

Flutamide is a first-generation nonsteroidal antiandrogen, used for treatment of advanced
prostate cancer (PCa). We present the clinical case of a patient with localized high-risk PCa …

Objectives To determine the anti‐androgenic effects and safety of the combination of
finasteride and flutamide in men with prostate cancer. Patients and methods Seventeen men …

Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen
(PSA) after flutamide withdrawal in a subset of patients with progressing metastatic …